Effect of Antacid Use on Immune Checkpoint Inhibitors in Advanced Solid Cancer Patients: A Systematic Review and Meta-analysis

Deng, Ruiyi; Zhang, Hua; Li, Yuan; Shi, Yanhong

doi:10.1097/cji.0000000000000442

Cited by 8 publications

(2 citation statements)

References 126 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results were in good agreement with the meta-analysis of Deng et al. (n = 16,147 patients, 30 publications) ( 57 ) and Chen et al. (n = 15,957 patients, 33 studies) ( 58 ).…”

Section: Discussionsupporting

confidence: 91%

Do proton pump inhibitors alter the response to immune checkpoint inhibitors in cancer patients? A meta-analysis

et al. 2023

View full text Add to dashboard Cite

IntroductionGut microbiota can significantly affect the effectiveness of immune checkpoint inhibitors (ICIs) in cancer patients. Recently, antibiotics were shown to decrease survival rate of patients treated by ICIs. Proton pump inhibitors (PPIs) can indeed modulate microbiota’s diversity, therefore altering ICIs response. A meta-analysis was performed based on published data to verify this hypothesis.MethodsIn this study, over 41 publications, exploring the impact of concomitant PPI treatment on outcomes of ICI-treated patients, were analyzed. Evaluated endpoints were overall survival (OS) and progression-free survival (PFS). Pooled hazard ratios (HRs) with a 95% confidence interval (CI) were reported in ICIs in PPI users versus non-PPI users. Subgroup analyses were performed to minimize the impact of study heterogeneity and to investigate the influence of PPI on the different groups of interest. There was no evidence of publication bias for OS and PFS analysis in subgroup analysis.ResultsForty-one studies were included in the meta-analysis, including a total of 20,042 patients. OS of patients receiving ICIs was negatively correlated in patients concomitantly treated with PPI (HR=1.37; 95%CI, 1.23–1.52). PFS of cancer patients receiving ICIs was also negatively correlated with PPI treatment (HR=1.28; 95%CI, 1.15–1.42). PPI and ICI use was associated with worst OS and PFS not only for non-small-cell lung cancer (NSCLC) or urothelial cancer patients but also for patients treated with anti PD-1 (OS) and anti PD-L1 (OS and PFS) immunotherapies when administered in non-first line and when PPI was received as baseline treatment or in 60 days before ICI initiation. PPI and ICI use also showed the worst OS and PFS for patients from Europe and Asia.ConclusionThis meta-analysis suggests that PPI treatment leads to significantly worse outcomes in advanced cancer patients treated by ICIs in terms of PFS and OS.

show abstract

“…These results were in good agreement with the meta-analysis of Deng et al. (n = 16,147 patients, 30 publications) ( 57 ) and Chen et al. (n = 15,957 patients, 33 studies) ( 58 ).…”

Section: Discussionsupporting

confidence: 91%

Do proton pump inhibitors alter the response to immune checkpoint inhibitors in cancer patients? A meta-analysis

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Additionally, this study revealed no significant difference in the occurrence of adverse reactions during the course of ICI combined therapy between the PPI and non-PPI groups, consistent with the findings of several other studies. 28–30 However, other studies have reported an association between the use of PPIs and an increased incidence of adverse reactions related to ICIs. 11 , 31 The relationship between PPIs and the occurrence of immune-related adverse events in patients remains inconclusive.…”

Section: Discussionmentioning

confidence: 97%

The Impact of Proton Pump Inhibitors on the Efficacy of Immune Checkpoint Inhibitor Combinations in Patients with HBV-Associated Advanced Hepatocellular Carcinoma

Wang,

Xu,

Yang

et al. 2024

JHC

View full text Add to dashboard Cite

Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study

Fiala,

Buti,

Takeshita

et al. 2023

Cancer Immunol Immunother

View full text Add to dashboard Cite

Effect of Antacid Use on Immune Checkpoint Inhibitors in Advanced Solid Cancer Patients: A Systematic Review and Meta-analysis

Cited by 8 publications

References 126 publications

Do proton pump inhibitors alter the response to immune checkpoint inhibitors in cancer patients? A meta-analysis

Do proton pump inhibitors alter the response to immune checkpoint inhibitors in cancer patients? A meta-analysis

The Impact of Proton Pump Inhibitors on the Efficacy of Immune Checkpoint Inhibitor Combinations in Patients with HBV-Associated Advanced Hepatocellular Carcinoma

Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study

Contact Info

Product

Resources

About